Cumberland Pharmaceuticals
CompanyUnited States
Cumberland Pharmaceuticals develops 5 assets, the furthest approved (Kristalose in acute and chronic constipation). Mostly small molecule acting on AVPR1A, AVPR2 and TBXA2R; based in the United States.
- 5
- Assets
- Furthest stage
- Approved
- 34
- Trials
- 8
- Signals
Pipeline
5Synthetic non-absorbable disaccharide osmotic laxative promoting intestinal motility.
Approved, Small molecule, acute and chronic constipation, anal fissure (Phase 3)
Approved, Small molecule, Helicobacter pylori infection
Blocks vasopressin V1A and V2 receptors, promoting free-water excretion and reducing vasopressin-mediated vasoconstriction.
Approved, Small molecule, AVPR1A, AVPR2, euvolemic and hypervolemic hyponatremia, acute decompensated heart failure (Phase 3)
2 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials44
- Deals3
- People6
- Signals13
- Similar companies6